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repositioning strategy following understanding of interacting dis-
eases can be effectively applied for the treatment for tuberculosis.
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Background: Tuberculosis remains as one of the highest unre-
olved disease burden among re-emerging diseases in Malaysia for
he last thirty years. Since 1980 s, Isoniazid Preventive Therapy has
een adopted for paediatric population in Malaysia. More recently,
t has been extended to the people living with HIV. With current
reatment protocol emphasizing among the infectives, we seek to
nd if combination treatment of these active cases with Isoniazid
reventive therapy for other high risk latent tuberculosis infection
roups among non-HIV population would give greater impact on
educing incidence.
Methods: This study aims to apply the use of infectious disease
odelling to study the progression of latent tuberculosis infection
mong non-HIV population inMalaysia, and to assess the impact of
soniazid as preventive therapy on reducing incidence. We present
deterministic compartmental age-structured tuberculosis model
hich incorporates treatmentof infectives aswell as thepreventive
herapy. The model assumes latently infected individuals develop
ctive disease as a result of primary infection, endogenous reac-
ivation and exogenous reinfection. We start by formulating and
nalyzing the model without any intervention strategy then, we
xtend to incorporate the preventive therapy and treatment of
nfectives. The epidemic thresholds known as reproduction num-
ers and equilibria for the model were determined, and stabilities
nalyzed. The reproduction numbers for themodelwere compared
o assess the possible community beneﬁts achieved by treatment
f infectives, preventive therapy and a holistic approach of com-
ination of both intervention strategies. The model then further
uantiﬁes the effectiveness of preventive therapy for early latent
uberculosis infection and demonstrates how effective the therapy
as to be to eliminate tuberculosis, when use in conjunction with
reatment for active tuberculosis.
Results: The analysis shows that additional coverage and treat-
ent of infectives among non-HIV population is more effective in
heﬁrst yearsof implementationof thispreventive therapyas treat-
ent results in clearing active tuberculosis immediately and there
fter preventive therapy will do better in controlling number of
nfectives due to reduced progression to infectious state.
Conclusion: Our model suggests that Isoniazid Preventive
herapy which identify and treat persons recently infected may
ave a substantial effect on controlling tuberculosis epidemics in
alaysia.
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Drug repositioning of latent TB
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Background: Mycobacterium tuberculosis (Mtb), the aetiologi-
cal agent of tuberculosis, kills about 1.7 million people per year
and is present in a latent form in about one-third of world’s pop-
ulation. Glycosyltransferases and Glycosyl hydrolases catalyse the
synthesis of important glycoconjugates, including glycolipids (PIM,
LAM, andAG), glycoproteins, and polysaccharide offers the suitable
drug targets. Drug repositioning provides immense opportunity
and provides solutions for increasing time, cost and failure of novel
drug discovery process. The pharmaceutical companies showed
less interest in TB due to less proﬁt in marketing and huge cost
of developing a drug. Hence drug repositioning can be a alternative
way to ﬁght against TB.
Here we have used computational functional genomics method
to predict the novel carbohydrate active enzymes from Mtb
genome, followedbydrug repositioningof the selected genes based
on their involvement in TB latency.
Methods: The functional re-annotation of glycogenome of
M.tuberculosis H37Rv on computational functional genomics, fold
recognition methods was performed. 14 glycome related genes
reported as top 500 ranked genes in latency by TargetDB (Dac B1,
PurF, Rv0486, Rv0648, Rv1082, Rv1090, Rv1170, Rv1987, Rv2006,
Rv2188c, Rv2402, Rv3487c, Rv1922, and Rv2619c) were selected.
The structure of the proteins was modelled using Modeler 9v9.
The network of TB co-infection with other diseases based on the
epidemiological literature available between year 1966-2012 was
created using Cytoscape and drugs used for those indications were
used for docking analysis.
Results: The functional re-annotation of glycogenome of
M.tuberculosis H37Rv revealed ∼260 new glycome related genes
including severalGTs, GH, and secretedglycoproteins important for
cell wall biosynthesis, virulence and other cellularmetabolism. The
epidemiological data suggested co-existence and reactivation of
latent tuberculosis during chronic disorders and immunocompro-
mised individuals with opportunistic infections. The anti-diabetic
drugs, nucleotide analogs used for cancer treatment, HIV, proto-
zoan disease showed novel interaction with the TB drug targets.
Conclusion: The chance of Disease-Target-Drug interaction
during this co-infection was more and exempliﬁes the survival
strategy of tuberculosis infection. This knowledge driven drug
